Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Senior Director of Target Biology
Compensation as of Fiscal Year 2014.
AnaptysBio, Inc. Key Developments
AnaptysBio, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 04:00 PM
Sep 10 14
AnaptysBio, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 04:00 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
AnaptysBio, Inc. Presents at BIO International Convention, Jun-25-2014 10:45 AM
Jun 17 14
AnaptysBio, Inc. Presents at BIO International Convention, Jun-25-2014 10:45 AM. Venue: San Diego Convention Center, San Diego, California, United States.
AnaptysBio, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 08:30 AM
Mar 19 14
AnaptysBio, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 08:30 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions